At present, withdrawal of clozapine is the mandatory choice in patients who develop cardiac adverse effects, and in these three patients we did not try to resume treatment. Recent case reports, however, suggest that clozapine might be safely resumed after starting treatment for heart failure in patients with otherwise refractory schizophrenia who develop left ventricular dysfunction. A clinical trial is needed to evaluate if early treatment with b blockers and ACE inhibitors may allow the progression of treatment after the development of mild signs of cardiac toxicity in resistant schizophrenia responsive to clozapine.
Clozapine associated cardiomyopathy: a cluster of 3 cases / C.Rostagno; S.Domenichetti; F.Pastorelli; G.F.Gensini. - In: INTERNAL AND EMERGENCY MEDICINE. - ISSN 1970-9366. - STAMPA. - 6:(2011), pp. 281-283. [10.1007/s11739-010-0468-4]
Clozapine associated cardiomyopathy: a cluster of 3 cases
ROSTAGNO, CARLO;GENSINI, GIAN FRANCO
2011
Abstract
At present, withdrawal of clozapine is the mandatory choice in patients who develop cardiac adverse effects, and in these three patients we did not try to resume treatment. Recent case reports, however, suggest that clozapine might be safely resumed after starting treatment for heart failure in patients with otherwise refractory schizophrenia who develop left ventricular dysfunction. A clinical trial is needed to evaluate if early treatment with b blockers and ACE inhibitors may allow the progression of treatment after the development of mild signs of cardiac toxicity in resistant schizophrenia responsive to clozapine.File | Dimensione | Formato | |
---|---|---|---|
Rostagno 2011 OK.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
221.78 kB
Formato
Adobe PDF
|
221.78 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.